Evaluate the Safety and Effectiveness of iSTAR Medical's MINIject™ Implant for Lowering Intraocular Pressure (IOP) in Subjects With Primary Open-angle Glaucoma.

Launched by ISTAR MEDICAL · Aug 23, 2021

Keywords

ClinConnect Summary

This clinical trial is looking at a new treatment called the MINIject™ implant from iSTAR Medical, which aims to help lower eye pressure in people with a condition known as primary open-angle glaucoma. Glaucoma is a disease that can damage the optic nerve and lead to vision loss, often because of high pressure inside the eye. The trial is currently recruiting participants who are 46 years or older and have been diagnosed with primary open-angle glaucoma. To qualify for the study, participants should have already had cataract surgery and may be considering other treatments like medication or laser therapy.

If you participate in this trial, you will receive the MINIject™ implant, and the researchers will closely monitor how well it works and how safe it is for you. However, this study is not for everyone. Those with certain types of glaucoma other than primary open-angle, serious eye infections, or certain vision disorders will not be eligible. This trial is an important step in finding new ways to help manage glaucoma and protect vision for those affected by this condition.

Gender

ALL

Eligibility criteria

• Key Inclusion Criteria:
• • Males and females, 46 years of age or older
• • A diagnosis of primary open-angle glaucoma, who are candidates for medical therapy, laser treatment, or glaucoma-filtering surgery
• • Pseudophakic with prior uncomplicated cataract surgery
• Key Exclusion Criteria:
• • Angle closure, congenital, or secondary glaucoma
• • Diagnosed degenerative visual disorders
• • Clinically significant intraocular inflammation or infection